Paper Details

  1. Home
  2. Paper Details

Experience with 9-cis retinoic acid in patients with relapsed and refractory non-Hodgkin's lymphoma.

Author: CabanillasF, CristofanilliM, HagemeisterF B, McLaughlinP, MesinaO, WeberD, YounesA

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Clinical Trial, Phase IIA Phase II trial is a trial that further evaluates the efficacy and safety of a new drug or treatment, whose safety has been confirmed to some extent in a Phase I trial, in a small number of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

A phase II study was conducted on 9-cis RA to determine its effectiveness in treating relapsed and refractory non-Hodgkin's lymphoma (NHL). 14% of patients showed a response (3 partial remissions and 1 complete remission), and the most common side effects were dry skin, headache, hypertriglyceridemia, and hypercalcemia.
Paper Details　
Original Abstract of the Article :
We conducted a phase II study to determine the efficacy and toxicity of 9-cis-retinoic acid (9-cis RA), a pan-retinoid receptor agonist, in the treatment of patients with relapsed and refractory NHL. Patients were eligible if they had histologically documented relapsed or refractory T cell or indole...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.3109/10428190009054883

データ提供：米国国立医学図書館（NLM）

9-cis Retinoic Acid: A New Hope for Relapsed and Refractory Non-Hodgkin's Lymphoma

Non-Hodgkin's lymphoma (NHL), a type of cancer affecting the lymphatic system, can be challenging to treat, particularly in cases of relapse or refractory disease. This research investigates the efficacy and toxicity of 9-cis-retinoic acid (9-cis RA), a pan-retinoid receptor agonist, in patients with relapsed and refractory NHL.

Modest Activity: A New Avenue for Treatment

The study, a phase II trial, evaluated the effectiveness of 9-cis RA in patients with relapsed and refractory NHL. The results showed modest activity, with a response rate of 14% in the study population. While this response rate may not be considered a dramatic breakthrough, it offers hope for patients who have exhausted other treatment options. Imagine a desert traveler who has been lost for days and stumbles upon a small oasis, offering respite and hope for survival. 9-cis RA, while not a complete solution, might offer a similar respite for some patients with relapsed and refractory NHL.

Navigating Treatment Options: Weighing the Benefits and Risks

The authors acknowledge the modest activity of 9-cis RA and highlight the need for further research to optimize its therapeutic potential. They also note the importance of carefully managing the drug's potential toxicities, including dry skin, headache, hypertriglyceridemia, and hypercalcemia. The study encourages a careful assessment of individual patient characteristics and the potential benefits and risks associated with this treatment approach.

Dr. Camel's Conclusion

The fight against cancer can be a long and arduous journey, like navigating a vast and unforgiving desert. This research explores a new avenue for treatment, using 9-cis RA as a potential source of hope for patients with relapsed and refractory NHL. While the path ahead may be challenging, this research offers a glimmer of hope for those facing this difficult disease.
Date :
  1. Date Completed 2001-09-27
  2. Date Revised 2019-01-16
Further Info :

Pubmed ID

11426631

DOI: Digital Object Identifier

10.3109/10428190009054883

Related Literature

Article Analysis
・Side Effects of alitretinoin
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.